GSK won U.S. approval for its second lung cancer drug from the Nuvalent deal

Summary
The FDA granted accelerated approval to neladalkib, sold as Nelkarmi, for ALK-positive non-small cell lung cancer
Description from Quartz.
Who is covering this
-
FDA Adds Another Player in ALK-Positive Lung Cancer
(MedPage Today) -- The FDA granted accelerated approval to the third-generation ALK inhibitor neladalkib (Nelkarmi) for previously treated advanced ALK-positive non-small cell lung cancer (NSCLC), making it the seventh approved agent in a crowded...
-
GSK won U.S. approval for its second lung cancer drug from the Nuvalent deal
The FDA granted accelerated approval to neladalkib, sold as Nelkarmi, for ALK-positive non-small cell lung cancer







Comments
Comments need JavaScript.